Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Toripalimab plus chemotherapie voor gerecidiveerd of gemetastaseerd nasofarynxcarcinoom
mrt 2024 | Hoofd-halsoncologie